Petros Pharmaceuticals Stock Annual Yield
PTPI Stock | USD 0.29 0.02 7.41% |
Petros Pharmaceuticals fundamentals help investors to digest information that contributes to Petros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Petros Stock. The fundamental analysis module provides a way to measure Petros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Petros Pharmaceuticals stock.
Petros | Annual Yield |
Petros Pharmaceuticals Company Annual Yield Analysis
Petros Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Petros Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Petros Pharmaceuticals is extremely important. It helps to project a fair market value of Petros Stock properly, considering its historical fundamentals such as Annual Yield. Since Petros Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Petros Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Petros Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, Petros Pharmaceuticals has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
All Next | Launch Module |
Petros Fundamentals
Return On Equity | -0.64 | ||||
Return On Asset | -0.31 | ||||
Profit Margin | (1.71) % | ||||
Operating Margin | (1.60) % | ||||
Current Valuation | 26.75 M | ||||
Shares Outstanding | 10.01 M | ||||
Shares Owned By Insiders | 8.10 % | ||||
Shares Owned By Institutions | 2.20 % | ||||
Number Of Shares Shorted | 199.19 K | ||||
Price To Book | 0.87 X | ||||
Price To Sales | 0.66 X | ||||
Revenue | 5.82 M | ||||
Gross Profit | 6.21 M | ||||
EBITDA | (4.21 M) | ||||
Net Income | (8.16 M) | ||||
Cash And Equivalents | 13.3 M | ||||
Cash Per Share | 0.64 X | ||||
Total Debt | 8.28 M | ||||
Debt To Equity | 0.31 % | ||||
Current Ratio | 3.10 X | ||||
Book Value Per Share | 4.04 X | ||||
Cash Flow From Operations | (7.63 M) | ||||
Short Ratio | 0.72 X | ||||
Earnings Per Share | (3.80) X | ||||
Target Price | 1.0 | ||||
Number Of Employees | 21 | ||||
Beta | 2.28 | ||||
Market Capitalization | 2.7 M | ||||
Total Asset | 33.8 M | ||||
Retained Earnings | (98.89 M) | ||||
Working Capital | 9.62 M | ||||
Net Asset | 33.8 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out Petros Pharmaceuticals Piotroski F Score and Petros Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.